Completed OBSERVATIONAL NCT04980040

A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea

Post Marketing Surveillance Protocol for Nesina® Tablet [Monotherapy or Combination Therapy in Type 2 Diabetic Patients]

Sponsor: Takeda

Conditions Type 2 Diabetes Mellitus

Interventions Alogliptin Benzoate

Updated 5 times since 2021 Last updated: Mar 31, 2022 Started: Apr 19, 2014 Primary completion: Aug 30, 2019 Completion: Aug 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Takeda and has accumulated 5 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
May 2022 — Jul 2024 [monthly]

Completed
Sep 2021 — May 2022 [monthly]

Completed

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Andong, South Korea , Anyang-si, South Korea , Bucheon-si, South Korea , Busan, South Korea , Daegu, South Korea , Daejeon, South Korea , Gimhae, South Korea , Gongju, South Korea , Goyang-si, South Korea , Gwangju, South Korea and 12 more locations